PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

被引：0

作者：

Paz-Ares, L. ^{[1
]}

Goldman, J. W. ^{[2
]}

Garassino, M. C. ^{[3
]}

Dvorkin, M. ^{[4
]}

Trukhin, D. ^{[5
]}

Statsenko, G. ^{[6
]}

Hotta, K. ^{[7
]}

Ji, J. H. ^{[8
]}

Hochmair, M. J. ^{[9
]}

Voitko, O. ^{[10
]}

Havel, L. ^{[11
]}

Poltoratskiy, A. ^{[12
]}

Losonczy, G. ^{[13
]}

Reinmuth, N. ^{[14
]}

Shrestha, Y. ^{[15
]}

Patel, N. ^{[16
]}

Mann, H. ^{[17
]}

Jiang, H. ^{[18
]}

Ozguroglu, M. ^{[19
]}

Chen, Y. ^{[20
]}

机构：

[1] Univ Hosp 12 Octubre, Med Oncol, Madrid, Spain

[2] Univ Calif Los Angeles, David Geffen Sch Med, Div Med, Los Angeles, CA 90095 USA

[3] Ist Nazl Tumori, Fdn IRCCS, Thorac Unit, Milan, Italy

[4] BHI Omsk Reg Clin Oncol Dispensary, Dept Oncol, Omsk, Russia

[5] Natl Med Univ, Oncol Dept, Odessa, Ukraine

[6] Omsk Reg Canc Ctr, Dept Med Oncol, Omsk, Russia

[7] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan

[8] Sungkyunkwan Univ, Sch Med, Samsung Changwon Hosp, Dept Internal Med, Chang Won, South Korea

[9] Krankenhaus Nord, Dept Resp & Crit Care Med, Karl Landsteiner Inst Lung Res & Pulm Oncol, Krankenhaus Nord, Vienna, Austria

[10] Kyiv City Clin Oncol Ctr, Dept Chemotherapy, Kiev, Ukraine

[11] Charles Univ Prague, Thomayer Hosp, Fac Med 1, Prague, Czech Republic

[12] Petrov Res Inst Oncol, Dept Preclin & Clin Trials, St Petersburg, Russia

[13] Semmelweis Univ, Fac Med, Budapest, Hungary

[14] Asklepios Lung Clin, Thorac Oncol, Munich, Germany

[15] AstraZeneca, Translat Med, Gaithersburg, MD USA

[16] AstraZeneca, Patient Reported Outcomes, Gaithersburg, MD USA

[17] AstraZeneca, Res & Dev, Cambridge, MD USA

[18] AstraZeneca, Global Med Dev, Gaithersburg, MD USA

[19] Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Dept Internal Med, Istanbul, Turkey

[20] Canc & Hematol Ctr Western Michigan, Med Oncol, Grand Rapids, MI USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA89

引用

页码：928 / +

页数：2

共 50 条

[1] Population Pharmacokinetics and Exposure-Response with Durvalumab Plus Platinum-Etoposide in ES-SCLC: Results from CASPIAN
Zheng, Y.
Jin, D.
Guan, Y.
Ozguroglu, M.
Trukhin, D.
Poltoratskiy, A.
Chen, Y.
Havel, L.
Hochmair, M.
Paz-Ares, L.
Jiang, H.
Armstrong, J.
Chen, C.
Liu, Y. H.
Roskos, L.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S508 - S508
[2] Durvalumab ± Tremelimumab plus Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN
Garassino, M. C.
Shrestha, Y.
Xie, M.
Lai, Z.
Spencer, S.
Dalvi, T.
Paz-Ares, L.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S939 - S939
[3] Durvalumab ± tremelimumab plus platinum-etoposide in 1L ES-SCLC: exploratory analysis of HLA genotype and survival in CASPIAN
Alt, J.
Garassino, M. C.
Shrestha, Y.
Xie, M.
Lai, Z.
Spencer, S.
Dalvi, T.
Paz-Ares, L.
Reinmuth, N.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 54 - 55
[4] Durvalumab ± tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study
Grohe, C.
Paz-Ares, L. G.
Dvorkin, M.
Chen, Y.
Hotta, K.
Trukhin, D.
Statsenko, G.
Hochmair, M. J.
Ozguroglu, M.
Ji, J. H.
Voitko, O.
Poltoratskiy, A.
Verderame, F.
Havel, L.
Bondarenko, I.
Armstrong, J.
Byrne, N.
Jiang, H.
Goldman, J. W.
Reinmuth, N.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 149 - 149
[5] First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN
Reinmuth, N.
Garassino, M. C.
Trukhin, D.
Hochmair, M. J.
Ozguroglu, M.
Havel, L.
Goldman, J.
Chen, Y.
Losonczy, G.
Spinnato, F.
Conev, N.
Bar, J.
Broadhurst, H.
Byrne, N.
Jiang, H.
Paz-Ares, L.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S500 - S500
[6] Durvalumab(D) ± tremelimumab(T) plus platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN
Saito, Haruhiro
Goldman, Jonathan W.
Garassino, Marina Chiara
Chen, Yuanbin
Reinmuth, Niels
Hotta, Katsuyuki
Poltoratskiy, Artem
Trukhin, Dmytro
Hochmair, Maximilian J.
Ozguroglu, Mustafa
Ji, Jun Ho
Statsenko, Galina
Voitko, Oleksandr
Conev, Nikolay V.
Bondarenko, Igor
Spencer, Stuart
Xie, Mingchao
Jones, Stephanie
Franks, April
Shrestha, Yashaswi
Paz-Ares, Luis
ANNALS OF ONCOLOGY, 2021, 32 : S289 - S289
[7] Durvalumab ± tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.
Paz-Ares, Luis G.
Dvorkin, Mikhail
Chen, Yuanbin
Reinmuth, Niels
Hotta, Katsuyuki
Trukhin, Dmytro
Statsenko, Galina
Hochmair, Maximilian
Ozguroglu, Mustafa
Ji, Jun Ho
Voitko, Oleksandr
Poltoratskiy, Artem
Verderame, Francesco
Havel, Libor
Bondarenko, Igor
Armstrong, Jon
Byrne, Natalie
Jiang, Haiyi
Goldman, Jonathan Wade
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes
Schulz, C.
Chen, Y.
Paz-Ares, L. G.
Dvorkin, M.
Trukhin, D.
Reinmuth, N.
Garassino, M. C.
Statsenko, G.
Voitko, O.
Hochmair, M. J.
Ozguroglu, M.
Verderame, F.
Havel, L.
Losonczy, G.
Conev, N.
Hotta, K.
Ji, J. H.
Broadhurst, H.
Byrne, N.
Thiyagarajah, P.
Goldman, J. W.
Alt, J.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 144 - 145
[9] 1L Durvalumab (D) plus Platinum-Etoposide (EP) in Patients with advanced small cell Lung Cancer (ES-SCLC): Exploratory Analysis of SCLC molecular Subtypes in the CASPIAN Trial
Schulz, C.
Xie, M.
Chugh, P.
Broadhurst, H.
Lai, Z.
Whitston, D.
Paz-Ares, L.
Gay, C.
Byers, L.
Rudin, C. M.
Stewart, R.
Barrett, J. C.
Shrestha, Y.
Panse, J.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 56 - 56
[10] Durvalumab (D) plus platinum-etoposide (EP) in 1L extensive-stage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN
Xie, Mingchao
Chugh, Priti
Broadhurst, Helen
Lai, Zhongwu
Whitston, David
Paz-Ares, Luis
Gay, Carl
Byers, Lauren
Rudin, Charles M.
Stewart, Ross
Barrett, J. Carl
Shrestha, Yashaswi
Panse, Jens
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 145 - 145

← 1 2 3 4 5 →